This was similarly relevant to CRC, since combination therapy of trametinib with autophagy inhibitor chloroquine demonstrated significant antitumor effects in patient-derived xenografts (PDX) of BRAF-mutated CRC [131]. Here, BRAF is linked to colorectal carcinoma.